Breast Cancer Update

Featuring perspectives from Dr Charles E Geyer Jr, Dr Maryam Lustberg, Dr Rita Nanda and Dr Seth Wander, including the following topics:Breast Cancer Introduction: ESMO 2026; Recent FDA Approvals (0:00)ER-Positive Breast Cancer (5:01)HER2-Positive Breast Cancer (1:19:08)Triple-Negative Breast Cancer (1:48:54)CME information and select publications

Featuring an interview with Dr Erica Mayer, including the following topics:Risk Assessment and Genomic Assays for Hormone Receptor (HR)-Positive, HER2-Negative Localized Breast Cancer (0:00)Investigator Survey Results on Risk Assessment and Genomic Assays (20:07)Adjuvant CDK4/6 Inhibitors for High-Risk, HR-Positive, HER2-Negative Localized Breast Cancer (24:30)Investigator Survey Results on Adjuvant CDK4/6 Inhibitors (30:42)Tolerability and Other Practical Considerations with Adjuvant CDK4/6 Inhibitor Therapy (32:07)Investigator Survey Results on Tolerability and Other Practical Considerations with Adjuvant CDK4/6 Inhibitor Therapy (37:44)Adjuvant Oral Selective Estrogen Receptor Degraders (SERDs) for HR-Positive, HER2-Negative Localized Breast Cancer (39:05)Investigator Survey Results on Adjuvant Oral SERDs (43:02)Discussion of Questions from the Community (45:00)CME information and select publications

Featuring perspectives from Dr Sara M Tolaney, including the following topics:Management of adverse events associated with TROP2-targeting antibody-drug conjugates (0:00)Managing brain metastases in triple-negative breast cancer (6:30)EGFR x HER3-directed bispecific antibodies for metastatic triple-negative breast cancer (mTNBC) (9:11)PD-1/PD-L1 x VEGF-directed bispecific antibodies for mTNBC (12:31)CME information and select publications

Featuring perspectives from Dr Sara M Tolaney, including the following topics:Mechanistic effects and potential resistance mechanisms of antibody-drug conjugates (0:00)First-line treatment of metastatic triple-negative breast cancer (mTNBC) in patients eligible for immunotherapy (7:13)First-line treatment of mTNBC in patients ineligible for immunotherapy (13:02)Antibody-drug conjugates for previously treated HER2-low metastatic breast cancer (19:15)CME information and select publications

Featuring perspectives from Dr David W Cescon, including the following topics:Clinical treatment of BRCA-mutated metastatic triple-negative breast cancer (0:00)CNS activity of TROP2-directed antibody-drug conjugates (5:36)Autoimmune considerations with immunotherapy (10:09)Treatment of oligoprogressive advanced breast cancer (17:31)CME information and select publications